Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy

Sergey G. Klochkov; Margarita E. Neganova; Nagendra Sastry Yarla; Madhukiran Parvathaneni; Bechan Sharma; Vadim V. Tarasov; George Barreto; Sergey O. Bachurin; Ghulam Md Ashraf; Gjumrakch Aliev

doi:10.1016/j.semcancer.2017.10.010

Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy

Sergey G. Klochkov
, Margarita E. Neganova
, Nagendra Sastry Yarla
, Madhukiran Parvathaneni
, Bechan Sharma
, Vadim V. Tarasov
, George Barreto
, Sergey O. Bachurin
, Ghulam Md Ashraf
, Gjumrakch Aliev

Research output: Contribution to journal › Review article › peer-review

Abstract

Ras proteins have been reported to play key role in oncologic diseases. Ras proteins are associated with cellular membranes for its carcinogenic activities through post-translational modifications, including farnesylation. Farnesyltransferase is responsible for a type of Ras membrane targeting, which leads to cancer origin and progression. Inhibitors of farnesyltransferase have been developed as novel anticancer agents. In this review, the role of farnesyltransferase in cancer progression and development has been discussed. Further, the current status of development of farnesyltransferase inhibitors for cancer prevention and treatment has also been reviewed.

Original language	English
Pages (from-to)	128-134
Number of pages	7
Journal	Seminars in Cancer Biology
Volume	56
DOIs	https://doi.org/10.1016/j.semcancer.2017.10.010
Publication status	Published - Jun 2019
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cancer
Farnesyltransferase
Farnesyltransferase inhibitor
Ras protein
Therapy

Access to Document

10.1016/j.semcancer.2017.10.010

Cite this

@article{cd7d01f7a28e4a7b9b03868c51b8ff02,

title = "Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy",

abstract = "Ras proteins have been reported to play key role in oncologic diseases. Ras proteins are associated with cellular membranes for its carcinogenic activities through post-translational modifications, including farnesylation. Farnesyltransferase is responsible for a type of Ras membrane targeting, which leads to cancer origin and progression. Inhibitors of farnesyltransferase have been developed as novel anticancer agents. In this review, the role of farnesyltransferase in cancer progression and development has been discussed. Further, the current status of development of farnesyltransferase inhibitors for cancer prevention and treatment has also been reviewed.",

keywords = "Cancer, Farnesyltransferase, Farnesyltransferase inhibitor, Ras protein, Therapy",

author = "Klochkov, \{Sergey G.\} and Neganova, \{Margarita E.\} and Yarla, \{Nagendra Sastry\} and Madhukiran Parvathaneni and Bechan Sharma and Tarasov, \{Vadim V.\} and George Barreto and Bachurin, \{Sergey O.\} and Ashraf, \{Ghulam Md\} and Gjumrakch Aliev",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Ltd",

year = "2019",

month = jun,

doi = "10.1016/j.semcancer.2017.10.010",

language = "English",

volume = "56",

pages = "128--134",

journal = "Seminars in Cancer Biology",

issn = "1044-579X",

}

TY - JOUR

T1 - Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy

AU - Klochkov, Sergey G.

AU - Neganova, Margarita E.

AU - Yarla, Nagendra Sastry

AU - Parvathaneni, Madhukiran

AU - Sharma, Bechan

AU - Tarasov, Vadim V.

AU - Barreto, George

AU - Bachurin, Sergey O.

AU - Ashraf, Ghulam Md

AU - Aliev, Gjumrakch

PY - 2019/6

Y1 - 2019/6

N2 - Ras proteins have been reported to play key role in oncologic diseases. Ras proteins are associated with cellular membranes for its carcinogenic activities through post-translational modifications, including farnesylation. Farnesyltransferase is responsible for a type of Ras membrane targeting, which leads to cancer origin and progression. Inhibitors of farnesyltransferase have been developed as novel anticancer agents. In this review, the role of farnesyltransferase in cancer progression and development has been discussed. Further, the current status of development of farnesyltransferase inhibitors for cancer prevention and treatment has also been reviewed.

AB - Ras proteins have been reported to play key role in oncologic diseases. Ras proteins are associated with cellular membranes for its carcinogenic activities through post-translational modifications, including farnesylation. Farnesyltransferase is responsible for a type of Ras membrane targeting, which leads to cancer origin and progression. Inhibitors of farnesyltransferase have been developed as novel anticancer agents. In this review, the role of farnesyltransferase in cancer progression and development has been discussed. Further, the current status of development of farnesyltransferase inhibitors for cancer prevention and treatment has also been reviewed.

KW - Cancer

KW - Farnesyltransferase

KW - Farnesyltransferase inhibitor

KW - Ras protein

KW - Therapy

UR - https://www.scopus.com/pages/publications/85035094841

U2 - 10.1016/j.semcancer.2017.10.010

DO - 10.1016/j.semcancer.2017.10.010

M3 - Review article

C2 - 29100957

AN - SCOPUS:85035094841

SN - 1044-579X

VL - 56

SP - 128

EP - 134

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

ER -

Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this